ADVERTISEMENT
Log in here to read the desired article.
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 135 entries already.
Roche’s Genentech unit has licensed global rights outside South Korea to HM17321, Hanmi Pharm’s Phase 1 obesity candidate. The deal gives Hanmi $190 million (€163 million) upfront and could be worth up to $2.3 billion (€2.0 billion), including development, regulatory and commercial milestones. Hanmi is also eligible for tiered royalties on future sales.
Sweden’s Hansa Biopharma has confidentially filed paperwork with the U.S. Securities and Exchange Commission for a potential initial public offering of American depositary shares.
UK biotech Actimed Therapeutics has regained global rights to S-oxprenolol from the now-defunct Faraday Pharmaceuticals, giving it control of the experimental muscle-wasting drug across cancer cachexia, amyotrophic lateral sclerosis (ALS) and other potential indications.
Scottish biotech Mironid has raised $46 million (€40 million) in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD) through clinical development.
French biotech Evexta Bio will combine its rupitasertib with Roche’s giredestrant in a Phase 1b trial targeting second-line, ESR1-mutated advanced breast cancer.
AstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agreement.
Ipsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery.
Guido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue more than fivefold.
AstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported.
Novo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales.